These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 16774855

  • 21. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET, Namiki M.
    Prostate; 2009 Aug 01; 69(11):1222-34. PubMed ID: 19434660
    [Abstract] [Full Text] [Related]

  • 22. The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis.
    Secondini C, Wetterwald A, Schwaninger R, Thalmann GN, Cecchini MG.
    PLoS One; 2011 Jan 13; 6(1):e16078. PubMed ID: 21249149
    [Abstract] [Full Text] [Related]

  • 23. Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway.
    Ye L, Kynaston H, Jiang WG.
    J Urol; 2009 Jun 13; 181(6):2749-59. PubMed ID: 19375725
    [Abstract] [Full Text] [Related]

  • 24. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.
    Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nör J, McCauley LK, Taichman RS, Keller ET.
    Cancer Res; 2004 Feb 01; 64(3):994-9. PubMed ID: 14871830
    [Abstract] [Full Text] [Related]

  • 25. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
    Fritz V, Noël D, Bouquet C, Opolon P, Voide R, Apparailly F, Louis-Plence P, Bouffi C, Drissi H, Xie C, Perricaudet M, Müller R, Schwarz E, Jorgensen C.
    Stem Cells; 2008 Nov 01; 26(11):2981-90. PubMed ID: 18757301
    [Abstract] [Full Text] [Related]

  • 26. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
    Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, Qin GJ, Liang G, Li JN, Han XF, Liu DX.
    Mol Immunol; 2009 Sep 01; 46(15):2876-84. PubMed ID: 19643479
    [Abstract] [Full Text] [Related]

  • 27. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis.
    Haydon RC, Luu HH, He TC.
    Clin Orthop Relat Res; 2007 Jan 01; 454():237-46. PubMed ID: 17075380
    [Abstract] [Full Text] [Related]

  • 28. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC.
    Prostate; 2008 Jan 01; 68(1):92-104. PubMed ID: 18008334
    [Abstract] [Full Text] [Related]

  • 29. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M, Ishii G, Miyamoto S, Hasebe T, Nagai K, Yonou H, Hatano T, Ogawa Y, Ochiai A.
    Prostate; 2006 Nov 01; 66(15):1573-84. PubMed ID: 16927388
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y, Ma Y, Lu HP, Gao JH, Liang CS, Liu CZ, Zou JT, Wang HQ.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2284-9. PubMed ID: 19080333
    [Abstract] [Full Text] [Related]

  • 31. Bone morphogenetic proteins and their receptor signaling in prostate cancer.
    Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG.
    Histol Histopathol; 2007 Oct 20; 22(10):1129-47. PubMed ID: 17616940
    [Abstract] [Full Text] [Related]

  • 32. [Differential proteomic analysis and function study of human prostate carcinoma cells with different osseous metastatic tendency].
    Song DX, Chen AM, Guo FJ, Liao H, Xie BZ, Zhu B, Chen C.
    Zhonghua Yi Xue Za Zhi; 2008 Apr 29; 88(17):1197-201. PubMed ID: 18844116
    [Abstract] [Full Text] [Related]

  • 33. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
    Hsieh CL, Xie Z, Yu J, Martin WD, Datta MW, Wu GJ, Chung LW.
    Prostate; 2007 May 15; 67(7):685-91. PubMed ID: 17342752
    [Abstract] [Full Text] [Related]

  • 34. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis.
    Liao J, Schneider A, Datta NS, McCauley LK.
    Cancer Res; 2006 Sep 15; 66(18):9065-73. PubMed ID: 16982748
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Bone morphogenetic protein signaling inhibits hair follicle anagen induction by restricting epithelial stem/progenitor cell activation and expansion.
    Zhang J, He XC, Tong WG, Johnson T, Wiedemann LM, Mishina Y, Feng JQ, Li L.
    Stem Cells; 2006 Dec 15; 24(12):2826-39. PubMed ID: 16960130
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression.
    Yuen HF, McCrudden CM, Grills C, Zhang SD, Huang YH, Chan KK, Chan YP, Wong ML, Law S, Srivastava G, Fennell DA, Dickson G, El-Tanani M, Chan KW.
    Cancer Sci; 2012 Jun 15; 103(6):1145-54. PubMed ID: 22364398
    [Abstract] [Full Text] [Related]

  • 40. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
    Yonou H, Ochiai A, Ashimine S, Maeda H, Horiguchi Y, Yoshioka K, Ogawa Y, Hatano T, Tachibana M.
    Prostate; 2007 Jun 15; 67(9):999-1009. PubMed ID: 17440967
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.